$LQDA

Bloch Stephen M sold $14.0M of LQDA (indirect holdings)

Bloch Stephen M sold 196,111 indirectly-held shares of Liquidia Corp (LQDA) at an average of $71.45 ($71.37–$72.15, $14.01M total) across 4 trades over 2026-06-12 to 2026-06-15.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 16, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The newest information is the disclosed $14.0M open-market sale (196,111 shares) and the director’s post-transaction holdings (980,073 shares), with no 10b5-1 plan cited.

02

Market read

Traders may react to the disclosed insider selling size and the absence of a 10b5-1 plan, but there is no accompanying operational or financial update.

03

What to watch

The filing states the sales were not under a pre-arranged 10b5-1 plan, but it does not disclose the director’s broader compensation/financial needs or whether other holdings were adjusted concurrently.

Relevance 7/10Novelty 8/10Timing: Filed 2026-06-16; sale executed 2026-06-12 to 2026-06-15.

Background

This is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia director Stephen M. Bloch sold $14.0M of LQDA shares via open-market transactions (Form 4) during 2026-06-12 to 2026-06-15.

Expected impact

Near-term: slight bearish bias; magnitude likely limited because it’s a disclosed Form 4 without new fundamentals.

Evidence & confidence

The article provides a concrete sale size, timing, and role (director) plus absence of a pre-arranged 10b5-1 plan, which traders may interpret as higher signaling risk.

Market effects

Limited sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity management and may not reflect company outlook, especially when multiple small trades are spread across days.

Key entities

  • Liquidia Corp

    US-listed company whose director insider sale is disclosed on Form 4.

  • Stephen M. Bloch

    Director reporting the open-market sale of LQDA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.